Edition:
India

Madrigal Pharmaceuticals Inc (MDGL.OQ)

MDGL.OQ on NASDAQ Stock Exchange Capital Market

108.91USD
25 Apr 2018
Change (% chg)

$0.10 (+0.09%)
Prev Close
$108.81
Open
$107.97
Day's High
$110.50
Day's Low
$104.31
Volume
60,319
Avg. Vol
85,781
52-wk High
$154.35
52-wk Low
$13.11

Chart for

About

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product,... (more)

Overall

Beta: 1.42
Market Cap(Mil.): $1,670.32
Shares Outstanding(Mil.): 14.23
Dividend: --
Yield (%): --

Financials

BRIEF-Madrigal Pharmaceuticals Qtrly ‍Loss Per Share $0.67​

* MADRIGAL PHARMACEUTICALS REPORTS 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, REVIEWS KEY CORPORATE ACHIEVEMENTS AND PROVIDES CLINICAL UPDATE ON MGL-3196

13 Mar 2018

BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Heterozygous Familial Hypercholesterolemia

* MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

08 Feb 2018

BRIEF-Madrigal Pharmaceuticals Prices Public Offering Of Common Stock

* MADRIGAL PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK

19 Dec 2017

BRIEF-Madrigal Pharma Announces Proposed Public Offering Of Common Stock

* MADRIGAL PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

18 Dec 2017

BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Biopsy-Proven Non-Alcoholic Steatohepatitis In Phase 2 Clinical Trial

* MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN PHASE 2 CLINICAL TRIAL

06 Dec 2017

BRIEF-Madrigal Pharmaceuticals reports Q3 loss per share of $0.68

* Madrigal Pharmaceuticals reports 2017 third quarter financial results

09 Nov 2017

Earnings vs. Estimates